Viking Therapeutics, Inc.
VKTX
$22.22
$0.703.25%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 15.25M | 13.77M | 10.29M | 9.97M | 8.78M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 46.24M | 36.56M | 34.05M | 34.07M | 29.29M |
| Operating Income | -46.24M | -36.56M | -34.05M | -34.07M | -29.29M |
| Income Before Tax | -35.42M | -24.94M | -22.25M | -27.36M | -24.61M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -35.42M | -24.94M | -22.25M | -27.36M | -24.61M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -35.42M | -24.94M | -22.25M | -27.36M | -24.61M |
| EBIT | -46.24M | -36.56M | -34.05M | -34.07M | -29.29M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.32 | -0.22 | -0.20 | -0.26 | -0.25 |
| Normalized Basic EPS | -0.20 | -0.14 | -0.13 | -0.17 | -0.15 |
| EPS Diluted | -0.32 | -0.22 | -0.20 | -0.26 | -0.25 |
| Normalized Diluted EPS | -0.20 | -0.14 | -0.13 | -0.17 | -0.15 |
| Average Basic Shares Outstanding | 111.34M | 110.91M | 110.39M | 103.46M | 99.94M |
| Average Diluted Shares Outstanding | 111.34M | 110.91M | 110.39M | 103.46M | 99.94M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
